HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19.

Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti-inflammatory, antipyretic, and analgesic effects are applied against symptoms of respiratory infections, including SARS-CoV-2, as well as in other acute and chronic inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID-19 also revealed the gaps in our understanding of their mechanism of action, selectivity, and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDs-exacerbated respiratory disease (NERD). In this context, the consensus report summarizes currently available knowledge, novel discoveries, and controversies regarding the use of NSAIDs in COVID-19, and the role of NSAIDs in asthma and viral asthma exacerbations. We also describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA therapy and discuss a potential role of LTRA therapy in COVID-19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other eicosanoid pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eicosanoid pathways, in context of viral infections and exacerbations of asthma and allergic diseases. Finally, we identify and summarize the major knowledge gaps and unmet needs in current eicosanoid research.
AuthorsMilena Sokolowska, G Enrico Rovati, Zuzana Diamant, Eva Untersmayr, Jürgen Schwarze, Zuzanna Lukasik, Florentina Sava, Alba Angelina, Oscar Palomares, Cezmi A Akdis, Liam O'Mahony, Milos Jesenak, Oliver Pfaar, María José Torres, Marek Sanak, Sven-Erik Dahlén, Grzegorz Woszczek
JournalAllergy (Allergy) Vol. 77 Issue 8 Pg. 2337-2354 (08 2022) ISSN: 1398-9995 [Electronic] Denmark
PMID35174512 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antiviral Agents
  • Eicosanoids
Topics
  • Anti-Inflammatory Agents, Non-Steroidal (pharmacology, therapeutic use)
  • Antiviral Agents (pharmacology, therapeutic use)
  • Asthma (drug therapy)
  • Consensus
  • Eicosanoids (metabolism)
  • Humans
  • Hypersensitivity (drug therapy)
  • Inflammation (drug therapy)
  • SARS-CoV-2
  • COVID-19 Drug Treatment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: